Here, we expand the toolkit of transgenesis by characterizing two novel stable transgenic lines that were generated using the highly efficient
The lines provide proof‐of‐principle for the application of
This content will become publicly available on April 15, 2024
Here, we expand the toolkit of transgenesis by characterizing two novel stable transgenic lines that were generated using the highly efficient
The lines provide proof‐of‐principle for the application of
Melatonin levels are partially driven by the parenchyma volume of the pineal gland. Low urinary levels of 6‐sulfatoxymelatonin have been associated with increased risk of advanced prostate cancer, but the relationship between pineal gland volume and composition and prostate cancer risk has not been examined.
We utilized data from 864 men from the AGES‐Reykjavik Study with complete pineal gland volumes and urinary 6‐sulfatoxymelatonin measurements. Pineal parenchyma, calcification, and cyst volumes were calculated from brain magnetic resonance imaging. Levels of 6‐sulfatoxymelatonin were assayed from prediagnostic urine samples. We calculated Pearson correlation coefficients between parenchyma volume and urinary 6‐sulfatoxymelatonin levels. We used Cox proportional hazards regression to calculate multivariable hazard ratios (HRs) and 95% confidence intervals (95% CIs) comparing prostate cancer risk across parenchyma volume tertiles and across categories factoring in parenchyma volume, gland composition, and urinary 6‐sulfatoxymelatonin level.
Parenchyma volume was moderately correlated with urinary 6‐sulfatoxymelatonin level (
Although parenchyma volume is not associated with prostate cancer risk, pineal gland composition and other circadian dynamics may influence risk for prostate cancer. Additional studies are needed to examine the interplay of pineal gland volume, composition, and melatonin levels on prostate cancer risk.